Dopacone (Levodopa + Carbidopa + Entacapone) is indicated for the treatment of Parkinson’s disease. Dopacone (Levodopa + Carbidopa + Entacapone) can be used:

• To substitute (with equivalent strengths of each of the three components) carbidopa, levodopa, and entacapone previously administered as individual products.
• To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600mg or less and have not been experiencing dyskinesias.